SCHEDULE: Suvretta Capital Invests $30M in Veradermics Private Placement

Suvretta Capital Management and its affiliates have acquired 300,000 pre-funded warrants in Veradermics, Inc., strengthening their 9.9% stake in the company.

Summary

• Suvretta Capital Management and associated funds participated in a private placement with Veradermics, Inc. on May 1, 2026.
• The reporting group acquired 300,000 pre-funded warrants for a total consideration of approximately $30 million.
• Averill Master Fund purchased 149,000 warrants for $14,899,998.51, while Averill Madison Master Fund purchased 151,000 warrants for $15,099,998.49.
• The warrants have a nominal exercise price of $0.00001 per share and were purchased at $99.99999 per warrant.
• The reporting persons collectively hold beneficial ownership of 4,172,121 shares, representing 9.9% of the company's common stock.
• The investment was funded through the working capital of the respective funds.

Sentiment

Score: 8

Explanation: StockSavvy.ai views this as a strong positive signal; a $30 million commitment from a major institutional player like Suvretta Capital provides significant validation and financial runway for the company.

Positives

• Significant $30 million capital injection from a sophisticated institutional investor.
• Strong institutional backing from Suvretta Capital indicates high confidence in the company's valuation and prospects.
• The use of pre-funded warrants provides the company with immediate cash while allowing the investor to manage ownership thresholds.

Negatives

• The private placement results in potential dilution for existing shareholders as warrants are exercised into common stock.
• Concentrated ownership by a single institutional group could lead to significant influence over corporate governance.

Risks

• Beneficial ownership limitations of 9.99% restrict the funds' ability to exercise warrants fully if the total share count decreases.
• The number of shares issuable upon exercise may fluctuate based on changes in the total outstanding common stock.
• Market volatility may impact the value of the underlying common stock relative to the high purchase price of the warrants.

Future Outlook

The reporting persons acquired these securities for investment purposes and will continue to review their investment in the Issuer, potentially acquiring more shares or disposing of them based on market conditions and company performance.

Management Comments

• Mr. Cowen is the control person and managing member of Suvretta Capital and may be deemed to control the other Reporting Persons.

Industry Context

StockSavvy.ai notes that private placements of pre-funded warrants are a common mechanism in the biotech sector to provide rapid capital to companies while allowing institutional investors to remain below the 10% 'insider' threshold mandated by Section 16 of the Exchange Act.

Comparison to Industry Standards

• The 9.9% ownership cap is a standard protective measure used by institutional funds to avoid short-swing profit rules.
• A $30 million private placement is a substantial mid-stage financing event, comparable to recent raises by other clinical-stage biotechnology firms.
• The nominal exercise price of $0.00001 is typical for pre-funded warrants, effectively making them equivalent to common stock for economic purposes.

Corporate Governance

Stakeholder Impact

• Shareholders may face future dilution upon the exercise of the 300,000 warrants.
• The company gains $30 million in working capital to fund its strategic initiatives and operations.

Next Steps

• Potential exercise of pre-funded warrants by Suvretta Capital as ownership limits allow.
• Ongoing monitoring of the 9.99% beneficial ownership threshold by the reporting persons.

Key Dates

Recommendation

The significant $30 million investment by Suvretta Capital at a high valuation floor indicates strong institutional conviction in Veradermics' pipeline. This level of backing from a specialized healthcare investor often precedes positive clinical or strategic milestones.

Keywords

Veradermics, Suvretta Capital Management, Private Placement, Pre-Funded Warrants, Schedule 13D, Institutional Investment, Biotechnology, Equity Financing